Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Consolidated Net Income (2016 - 2025)

Standard Biotools (LAB) has disclosed Consolidated Net Income for 16 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income rose 178.01% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$39.4 million through Dec 2025, up 38.71% year-over-year, with the annual reading at -$16.1 million for FY2025, 66.48% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $5.4 million at Standard Biotools, up from -$3.0 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $13.7 million in Q4 2023, with the low at -$76.3 million in Q1 2022.
  • Average Consolidated Net Income over 5 years is -$20.3 million, with a median of -$17.2 million recorded in 2021.
  • The sharpest move saw Consolidated Net Income plummeted 305.82% in 2022, then skyrocketed 178.01% in 2025.
  • Over 5 years, Consolidated Net Income stood at -$13.9 million in 2021, then plummeted by 50.34% to -$20.8 million in 2022, then surged by 165.83% to $13.7 million in 2023, then plummeted by 150.27% to -$6.9 million in 2024, then surged by 178.01% to $5.4 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at $5.4 million, -$3.0 million, and -$15.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.